Cellebrite DI (CLBT)
Official siteTECHNOLOGY • SOFTWARE - INFRASTRUCTURE • NASDAQ
Market Cap: $2.90B
Last updated: Nov 17, 2026 at 11:05 AM ET
Cellebrite DI (CLBT) Earnings: Report Dates and Results
Cellebrite DI (CLBT) is expected to report earnings on Feb 9, 2027. In the quarter ended Sep 30, 2026, Cellebrite DI reported EPS of $0.13, above the $0.12 estimate. It beat the EPS estimate in 5 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
CLBT has an expected report date of Feb 9, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 28.6% above the $0.14 reported for the quarter ended Dec 31, 2025.
CLBT Earnings Call
The latest CLBT earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 22 quarters below that had an estimate, CLBT beat 16, missed 4 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $149.02M, up 18.2% from $126.03M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.13 | $0.12 | N/A | +8.33% | Beat | -7.1% | 8 | 5 up, 3 down | Nov 12, 2026 | $149.02M |
| Jun 30, 2026 | $0.05 | $0.09 | $0.09 - $0.13 | -44.44% | Miss | -58.3% | 8 | 2 up, 3 down | Aug 13, 2026 | $131.14M |
| Mar 31, 2026 | $0.12 | $0.10 | $0.08 - $0.11 | +20.00% | Beat | +20.0% | 6 | 0 up, 3 down | May 14, 2026 | $128.30M |
| Dec 31, 2025 | $0.14 | $0.14 | $0.11 - $0.16 | 0.00% | In line | +40.0% | 8 | 4 up, 3 down | Feb 11, 2026 | $128.82M |
| Sep 30, 2025 | $0.14 | $0.13 | $0.11 - $0.14 | +7.69% | Beat | 0.0% | 8 | 3 up, 3 down | Nov 12, 2025 | $126.03M |
| Jun 30, 2025 | $0.12 | $0.11 | $0.11 - $0.14 | +9.09% | Beat | +20.0% | 8 | 0 up, 1 down | Aug 14, 2025 | $113.28M |
| Mar 31, 2025 | $0.10 | $0.09 | $0.07 - $0.10 | +11.11% | Beat | +25.0% | 8 | 3 up, 0 down | May 14, 2025 | $107.55M |
| Dec 31, 2024 | $0.10 | $0.10 | $0.08 - $0.11 | 0.00% | In line | -16.7% | 8 | 2 up, 5 down | Feb 13, 2025 | $109.05M |
| Sep 30, 2024 | $0.14 | $0.09 | -$0.05 - $0.12 | +55.56% | Beat | +55.6% | 7 | 0 up, 0 down | Nov 6, 2024 | $106.86M |
| Jun 30, 2024 | $0.10 | $0.05 | -$0.07 - $0.08 | +100.00% | Beat | +100.0% | 8 | 0 up, 1 down | Aug 15, 2024 | $95.71M |
| Mar 31, 2024 | $0.08 | $0.06 | $0.05 - $0.06 | +33.33% | Beat | +166.7% | 6 | 0 up, 0 down | May 23, 2024 | $89.58M |
| Dec 31, 2023 | $0.12 | $0.06 | $0.05 - $0.07 | +100.00% | Beat | +50.0% | 5 | 0 up, 0 down | Feb 15, 2024 | $93.01M |
| Sep 30, 2023 | $0.09 | $0.05 | $0.04 - $0.05 | +80.00% | Beat | +800.0% | 4 | 0 up, 0 down | Nov 14, 2023 | $84.18M |
| Jun 30, 2023 | $0.05 | $0.02 | $0.01 - $0.03 | +150.00% | Beat | -70.6% | 6 | 1 up, 0 down | Aug 8, 2023 | $76.68M |
| Mar 31, 2023 | $0.03 | $0.02 | $0.01 - $0.04 | +50.00% | Beat | +200.0% | 4 | 0 up, 0 down | May 10, 2023 | $71.23M |
| Dec 31, 2022 | $0.08 | $0.07 | N/A | +14.29% | Beat | +166.7% | 4 | 0 up, 0 down | Feb 15, 2023 | $74.02M |
| Sep 30, 2022 | $0.01 | $0.02 | $0.00 - $0.04 | -50.00% | Miss | -87.5% | 4 | 0 up, 0 down | Nov 17, 2022 | $71.67M |
| Jun 30, 2022 | $0.17 | $0.03 | $0.00 - $0.05 | +466.67% | Beat | +240.0% | 5 | 0 up, 0 down | Aug 11, 2022 | $62.57M |
| Mar 31, 2022 | $0.01 | $0.02 | -$0.01 - $0.04 | -50.00% | Miss | -95.5% | 4 | 0 up, 0 down | May 12, 2022 | $62.38M |
| Dec 31, 2021 | $0.03 | $0.02 | $0.01 - $0.03 | +50.00% | Beat | N/A | 4 | 0 up, 0 down | Feb 16, 2022 | $67.91M |
| Sep 30, 2021 | $0.08 | $0.02 | $0.02 - $0.02 | +300.00% | Beat | N/A | 2 | N/A | Nov 10, 2021 | $65.89M |
| Jun 30, 2021 | $0.05 | $0.06 | N/A | -16.67% | Miss | N/A | 1 | N/A | Aug 6, 2021 | $59.17M |
| Mar 31, 2021 | $0.22 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 17, 2021 | $53.28M |
| Dec 31, 2020 | -$0.20 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 24, 2021 | $57.17M |
| Sep 30, 2020 | Not reported | N/A | N/A | N/A | Not reported | N/A | N/A | N/A | Nov 16, 2020 | $53.24M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $0.50, up 19.0% from the year before. It was -$0.20 for the year ended Dec 31, 2020, the oldest of the 6 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $0.50 | +19.0% |
| Dec 31, 2024 | $0.42 | +44.8% |
| Dec 31, 2023 | $0.29 | N/A |
| Dec 31, 2022 | $0.27 | -28.9% |
| Dec 31, 2021 | $0.38 | N/A |
| Dec 31, 2020 | -$0.20 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 5,700 words across 13 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 5,662 | 13 | |
| 2026Q2 | Jun 30, 2026 | 6,364 | 14 | |
| 2026Q1 | Mar 31, 2026 | 8,343 | 13 | |
| 2025Q4 | Dec 31, 2025 | 5,572 | 11 | |
| 2025Q3 | Sep 30, 2025 | 8,661 | 14 | |
| 2025Q2 | Jun 30, 2025 | 8,782 | 14 | |
| 2025Q1 | Mar 31, 2025 | 8,195 | 11 | |
| 2024Q4 | Dec 31, 2024 | 8,150 | 14 |
2026Q3 Earnings Call
Opening remarks
Andrew Kramer Vice President of Investor Relations Thank you, operator, and welcome to Cellebrite's Third Quarter 2026 Financial Results Call. I'm joined here this morning by our primary speakers: Shiven Ramji, Cellebrite's CEO, and David Barter, Cellebrite's CFO. Marcus Jewell, our CRO, will join for a Q&A session. This call is being recorded, and a replay will be made available on our website shortly after the call, along with a copy of our prepared remarks. Please note that today's press release and financial statements, including GAAP-to-non-GAAP reconciliations, are available on the Investor Relations website at investors.cellebrite.com. In addition to the press release, we posted other materials on the quarterly results page of our IR website, including a presentation to accompany our remarks, and that is embedded in your webcast viewer. We also added a link to a customer video, as well as our historical financial information and supplemental data for the first three quarters of 2026, each quarter of 2025, and the full years 2024 and 2023. Additionally, unless stated otherwise, our discussion of our third-quarter 2026 financial metrics, as well as the financial metrics provided in our outlook, will be done on a non-GAAP basis only, and all historical comparisons are with the comparable periods of 2025. I'd like to remind you that today's discussion will contain forward-looking statements, including, but not limited to, the company's business, operations, and financial performance. All forward-looking statements are subject to risks and uncertainties and other factors that could cause matters expressed or implied by those forward-looking statements not to occur. Actual results could also differ materially from historical results and/or from forecasts. Some of these forward-looking statements are discussed under the heading Risk Factors and elsewhere in the company's annual report on Form 20-F filed with the SEC on March 3, 2026. The company does not undertake to update any forward-looking statements to reflect future events or circumstances. Slide 3 outlines the agenda for today. And with that said, I'd now like to turn the call over to Shiven Ramji.
Shiven Ramji CEO Thank you, Andy, and good morning, everyone. Cellebrite executed better in Q3, with ARR, revenue, and adjusted EBITDA all finishing above our guidance. Our ARR and revenue growth were driven by strong international performance, while our U.S. federal business continued reaccelerating. Our top-line performance, combined with prudent spending, led to strong adjusted EBITDA and free cash flow. Together with our ARR growth, that produced another strong quarter of Rule of X performance. Dave will walk you through the quarterly performance details and our updated outlook. During the quarter, we made important strategic and operational progress. From a strategic perspective, I'm particularly excited about the direction of our product team and what we'll be releasing to customers.
Frequently Asked Questions About CLBT
When is Cellebrite DI's next earnings date?
Cellebrite DI's next earnings report is expected for Feb 9, 2027.
Did CLBT beat earnings estimates last quarter?
Yes. Cellebrite DI reported EPS of $0.13 for the quarter ended Sep 30, 2026, above the $0.12 estimate, a 8.33% surprise.
What EPS do analysts expect from CLBT next quarter?
The consensus EPS estimate for Cellebrite DI for the quarter ending Dec 31, 2026 is $0.18 from 10 analysts, with estimates from $0.16 to $0.20.
How often does CLBT beat earnings estimates?
Cellebrite DI beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +1.47%.
CLBT pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts